Through dedicated leaders Sean Rafferty and Claire Bothwell, the Australian chapter is helping to build the data that will eventually power human clinical trials.
Rare diseases don't respect time zones, so when the MEF2C Foundation Australia releases an update, families across Europe and the Americas are listening. When they wake up, that is.
The Volare Study is a Community Effort
One of the most significant milestones in the fight against MEF2C Haploinsufficiency Syndrome (MHS) was the delivery of the Volare Study's first patient-derived iPSC lines (induced pluripotent stem cells). Funded by the Rare Bird Foundation with a $1.1 million grant, this study is a massive, multi-institutional effort.
MEF2C Foundation Australia is a key pillar of this study, alongside:
- Weill Cornell Medical Center (NY)
- Weill Cornell Medical Center (Doha)
- Sidra Hospital (Doha)
- MEF2C Foundation (UK)
- MEF2C Foundation (US)
- Mef2c Hilfsorganisation (Germany)
This global distribution means that the research isn't driven by just one country's medical system, it's built on the collective data of families from multiple continents.
Faces of the Foundation
Charities are run by people. In Australia, the foundation's energy comes from dedicated parents like Sean Rafferty and Claire Bothwell, who have recently shared their story and the foundation's work on the MEF2Cast podcast.
In a recent episode titled "MEF2C Foundation Australia," they discussed the reality of living with MHS in a remote part of the world, the importance of connecting with the global community, and how the Volare Study gives Australian families a direct line to scientific progress. This followed "Balancing Care and Family Life," offering practical advice to other families navigating the daily challenges of MHS.
The Australian Chapter
Geographically, Australia is isolated, but scientifically, it's well connected. The Australian foundation represents the global reach of the MEF2C community, proving that a rare disease affecting fewer than 500 people worldwide can build a network that spans the entire globe.
Without the Australian foundation's participation in studies like Volare, the research would be missing a crucial piece of the puzzle. The data they contribute ensures that MHS isn't just understood through a European or American lens, but through a truly global one.
The Global Picture
The MEF2C Foundation Australia's active role in the Volare Study is a perfect example of the modern rare disease model: families in different time zones pooling their resources, data, and hope to build a path toward human trials. They are, quite literally, helping to turn research into reality.